Please provide your email address to receive an email when new articles are posted on . Wet age-related macular degeneration was one of the biggest topics at the AAO meeting this year. Tyrosine kinase ...
4FRONT-1 Phase 3 expected data readout accelerated from H2 2027 to H1 2027 4FRONT-2 Phase 3 trial initiated ahead of schedule Streamlined late-stage clinical and pre-commercial organization aligns ...
Ixo-vec is a potential best-in-class one-time gene therapy designed to deliver long-term efficacy, reduce the burden of frequent anti-VEGF and improve vision outcomes for patients with wet AMD ARTEMIS ...
Wet AMD in its early stages can be treated with drugs to reduce the formation of new blood vessels, but this treatment is inefficient in cases where blood vessel formation is already in its advanced ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company expects data from ...
Hosted on MSN
OCUL stock surges overnight ahead of crucial wet AMD data readout, Sanofi takeover buzz builds
The company is set to release topline results from its Phase 3 superiority trial of Axpaxli in wet AMD on Tuesday. Ocular previously said that positive results could support a New Drug Application ...
AMD primarily affects central vision, complicating activities like reading and driving, but does not cause complete blindness. Wet AMD involves abnormal blood vessel growth, while dry AMD progresses ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results